Introduction
The c-Abl protein is a tightly regulated nonreceptor tyrosine kinase that is involved in the regulation of cell proliferation, cell survival, cell adhesion, cell migration and apoptosis. The c-Abl protein is located both in the nucleus and the cytoplasm. In the nucleus, c-Abl protein is known to be activated in response to DNA damage and contributes to apoptosis (Wang, 2000) . Cytoplasmic c-Abl is associated with growth factor receptor signaling that can affect cell mobility and cell adhesion (Taagepera et al., 1998) . The oncogenic effects of Abl are believed to reside in cytoplasmic forms of c-Abl. Several studies have shown that c-Abl is downregulated in part by intramolecular interactions that provide autoinhibitory kinase effects (Pendergast, 2002; Pluk et al., 2002; Hantschel et al., 2003) . Studies have also found that c-Abl kinase activity is regulated by intermolecular interactions with negative regulators, which include Bcr (Liu et al., 1996; Ling et al., 2003) , PAG (Wen and Van Etten, 1997) , F-actin (Woodring et al., 2003) and phosphoinositides (Plattner and Pendergast, 2003) .
The c-Abl protein is widely expressed in all tissues and until recently oncogenically activated forms of Abl were believed to be restricted to hematopoietic malignancies, principally chronic myeloid leukemia (CML) and to a lesser degree in acute lymphocytic B-cell leukemia. Over 95% of CML patients have an abnormal chromosome 22 known as the Philadelphia chromosome (Ph). The Ph fuses 5 0 portions of BCR to the second exon of the c-ABL gene. The first exon of c-ABL encodes sequences involved in the autoinhibition of the c-Abl tyrosine kinase, so deletion of these sequences is thought to contribute to the activated state of the Abl tyrosine kinase domain.
Our recent findings demonstrate that activated c-Abl tyrosine kinase may also play a role in non-small cell lung cancer (NSCLC) (Lin et al., 2005 (Lin et al., , 2007 . Activation of c-Abl tyrosine kinase in some solid tumors is further supported by studies from Plattner and co-workers (Srinivasan and Plattner, 2006; Srinivasan et al., 2008) , whose findings indicate active c-Abl tyrosine kinase plays a role in aggressive human breast cancer cell lines.
Activated c-Abl in non-small cell lung cancer
Lung cancer, the leading cause of cancer-related mortalities in the United States (US Cancer Statistics Working Group, 2004) , is divided into two major subgroups, small cell lung carcinomas (SCLC) and NSCLC. Depending on the type and stage of the disease, treatment for lung cancer includes tumor resection, chemotherapy and radiation therapy. Recently, new approaches in the treatment of NSCLC have arisen from the discovery that the epithelial growth factor receptor (EGFR) is frequently overexpressed and activated in NSCLC (Bunn and Franklin, 2002; Dowell and Minna, 2005) . Importantly, loss of sequences within chromosome 3p is frequently seen in both SCLC and NSCLC, providing evidence of tumor suppressor genes (TSGs) in this chromosomal region (Girard et al., 2000; Zabarovsky et al., 2002) . The FUS1 gene has been identified in the 3p21.3 critical chromosomal region and is considered a novel TSG (Ji et al., 2002; Zabarovsky et al., 2002) .
Our studies showing that the c-Abl tyrosine kinase is involved in NSCLC began during a screening of synthetic peptides that had inhibitory activity towards the c-Abl tyrosine kinase in an assay involving the phosphorylation of a GST-Crk peptide. The c-Crk protein is a known target of the c-Abl kinase. Of interest, increased levels of c-Crk are associated with an aggressive phenotype in lung adenocarcinoma (Miller et al., 2003) . This screening assay revealed that a small peptide derived from sequences deleted in a mutant FUS1, that lacks tumor suppressor activity, strongly inhibited the recombinant 45 kDa Abl tyrosine kinase. This Fus1 peptide was not functional unless a stearate group was linked to the N terminus. (Lin et al., 2007) . At the time Fus1 was not known to be involved with c-Abl, nor was it known that Fus1 may be an inhibitor of the c-Abl tyrosine kinase. We verified Fus1's ability to downregulate Abl kinase by showing that the abovementioned Fus1 peptide strongly inhibited a purified full-length human-activated c-Abl tyrosine kinase (Lin et al., 2007) .
It has been shown that normal lung tissue expresses Fus1, whereas a majority of primary lung tumor samples do not express Fus1 (Uno et al., 2004) . A new study has shown that 100% of human SCLC tissue samples (22 samples) and 82% of human NSCLC tissue samples (281) had a loss or reduction of Fus1, while in contrast no normal or abnormal epithelial sites showed complete lack of Fus1 expression (Prudkin et al., 2008) . In addition, for NSCLC they found that loss of Fus1 expression is a significant independent adverse prognostic factor for overall patient survival (Prudkin et al., 2008) . The mechanism of Fus1 tumor suppressor activity is currently unknown. A deletion mutant of FUS1 (FUS1 (1-80)) has been isolated and characterized from human NSCLC cell lines; it lacks the last 30 amino acids encoded by the FUS1 gene (Kondo et al., 2001; Ji et al., 2002) . These deleted sequences encode the Abl inhibitory peptide sequences described above. Myristoylation of Fus1 at the N terminus is also required for the tumor suppressing function of FUS1. Myristoylation of Fus1 has been shown to increase the half-life of the Fus1 protein and appears to be involved in the regulation of the subcellular localization of Fus1 to the cytoplasm (Uno et al., 2004) (Figure 1 ). The lack of Fus1 myristoylation has been found in NSCLC primary tumors (Uno et al., 2004) . Of interest, the myristic acid, which is bound to the N-terminal segment of c-Abl isoform 1b, is thought to be involved in autoinhibition of c-Abl (Hantschel et al., 2003) .
In our studies, two human NSCLC cell lines (A549 and H1299) contained a tyrosine kinase active c-Abl protein as determined by immune complex kinase assays. Importantly, both cell lines are defective for the Fus1 protein expression (Kondo et al., 2001) . In Imatinib mesylate (TN Gleevec, Novartis Pharmaceuticals, East Hanover, NJ, USA) is widely known for its ability to inhibit the activated tyrosine kinase activity of c-Abl and Bcr-Abl (Buchdunger et al., 1996) . A previous study has shown that imatinib (Gleevec) inhibited the growth of NSCLC cell line A549 in vitro (Zhang et al., 2003) . We therefore tested the effects of imatinib on colony formation of H1299 cells in soft agar. Imatinib treatment (concentrations 1-5 mM) strongly inhibited the colony-forming ability of H1299 cells; both the number and size of colonies were inhibited (Lin et al., 2007) . We note that imatinib at these low concentrations had little effect on the proliferation of the H1299 cells in cell culture. So the primary inhibitory effects of imatinib were confined to the oncogenic behavior of H1299 cells, as measured by formation of growth of the cells in soft agar.
Possible mechanism of the inhibition of c-Abl tyrosine kinase by Fus1
Although identified as a TSG, the biochemical function of Fus1 protein is unknown. Clues as to its possible activities can be gained from structure-function relationships of wild type and mutant forms of the Fus1 protein (Figure 1) . A deletion mutant of FUS1 (FUS 1-80) lacks its tumor suppressor function (Lin et al., 2007) . Thus, the C-terminal 30 amino acids within the Fus1 protein is important for its tumor suppressor function and for its ability to downregulate c-Abl.
Our co-expression studies indicate that Fus1 (1-80) maintains its ability to associate with c-Abl (either directly or indirectly) despite it being defective in kinase inhibition (Lin et al., 2007) . Therefore, Fus1 and c-Abl associate through sequences within the first 80 amino acids of Fus1. In this regard, sequences surrounding the myristoylation site near the N terminus of Fus1 might also play some role in c-Abl kinase binding and possibly kinase inhibition (Figure 2 ). Detailed studies using X-ray crystallography indicate that the myristolation group at the N terminus of c-Abl 1b is one of the significant components of autoinhibition of c-Abl, as the myristoyl group is associated with a hydrophobic cleft within the catalytic domain of c-Abl (Hantschel et al., 2003) . Since the Fus1 inhibitory peptide requires the N-terminal stearate acid moiety for inhibitory activity (Lin et al., 2007) and since stearic acid and myristic acid are similar in structure (C18 compared to C15 fatty acids, respectively), the Abl kinase inhibition by Fus1 may require binding of both C-terminal Fus1 sequences, the myristoyl group itself and N-terminal sequences surrounding the myristolation site of Fus1 for effective c-Abl kinase inhibition (Figure 2 ).
Activated c-Abl in human breast cancer
Recent findings by Plattner and co-workers (Srinivasan and Plattner, 2006; Srinivasan et al., 2008) indicate that c-Abl may play an important role in breast cancer. Plattner's previous studies have shown that endogenous c-Abl is activated downstream of growth factors, such as EFGR and platelet-derived growth factor receptor (Plattner et al., 1999) . Human breast cancers have deregulated constitutively activated EGFR family members, including EGFR1 and ErbB2 (Ross and Fletcher, 1998) . Their initial study of active Abl kinases in breast cancer cell lines demonstrated that active Abl kinases, both c-Abl and Arg, promote invasion of aggressive human breast cancer cell lines (Srinivasan and Plattner, 2006) . Their results show that c-Abl directly binds to EGFR after EGF stimulation and this leads to activation of Abl kinase and that treatment of aggressive breast cancer cells with an EGFR inhibitor leads to a decrease in active Abl kinase. They also show that activated Src kinase in aggressive breast cancer cell lines can activate c-Abl kinase. While it has been shown that Src kinase is activated downstream of EGFR (Osherov and Levitzki, 1994) , Srinivasan and Plattner (2006) show that activated Src kinase can activate c-Abl kinase in an EGFR-independent manner. They further show that inhibition of Abl kinases, either by imatinib or siRNA, reduced the invasion of the aggressive breast cancer cells (Srinivasan and Plattner, 2006) .
Abl as a downstream target of Src in breast cancer is supported by a recent study that shows that a decrease of Src kinase by a known Src inhibitor leads to a decrease of Abl kinase human breast cancer cell lines (Sirvent et al., 2007) . Sirvent et al. (2007) further show that Abl is involved in a Src/Abl/Rac/JNK/STAT3 signaling cascade that is important in cell transformation. In addition, they also show that a Src/Abl/Rac/ ERK5 survival pathway is activated in human breast cancer cell lines.
A subsequent study (Srinivasan et al., 2008) indicates that Abl and Arg are required in breast cancer cell lines for other oncogenic events and properties including: phosphorylation of Stat3 (which activates pathways that are needed for breast cancer development and progression), anchorage-independent growth, inhibition of apoptosis caused by nutrient deprivation and accelerating G 1 -S phase transition. In an experiment similar to ours, Srinivasan et al. (2008) demonstrates that Abl kinase contributes to aggressive breast cancer anchorageindependent growth by inhibiting colony formation of breast cancer cells in soft agar through treatment with imatinib. Their findings also identified the insulin-like growth factor 1 receptor (IGF-1R) as a novel activator of Abl kinases. Importantly, they show that G 1 -S transition by IGF-1R requires activation of Abl kinases (Srinivasan et al., 2008) . Plattner and co-workers conclude that 'since activation of Abl kinases affects multiple steps of breast cancer development and progression, Abl kinase inhibitors are likely to be effective agents for treatment of breast cancers containing highly active Abl kinases'.
Implications of activated c-Abl tyrosine kinase in human NSCLC and human breast cancer
Since c-Abl is activated in some human cell lines of NSCLC that have reduced expression of the TSG FUS1 (Lin et al., 2007) , these findings raise the possibility that c-Abl may be a useful new target in FUS1-deficient NSCLC. This is important since NSCLC accounts for approximately 80% of all lung cancers. Currently, NSCLC patients have few options for therapy. Pioneering findings by John Minna (University of Texas Southwestern in Dallas) and Jack Roth (MD Anderson Cancer Center, Houston, TX, USA) and their coworkers have shown that most NSCLC patients have a deficiency in FUS1 expression (Ji et al., 2002; Zabarovsky et al., 2002) . Our studies indicate that one of the key targets of FUS1 protein is the c-Abl tyrosine kinase. Experiments on two NSCLC cell lines (A549 and H1299) show that these cells contain an activated Abl tyrosine kinase (Lin et al., 2007) . Importantly, both cell lines are defective for the Fus1 protein expression.
The H1299 cell line forms colonies in soft agar, indicating their ability to proliferate without the need Model for c-Abl activation in non-small cell lung cancer and breast cancer. Overexpression of epithelial growth factor receptor (EGFR) is present in both non-small cell lung cancer (NSCLC) and breast cancer (Ross and Fletcher, 1998; Bunn and Franklin, 2002) . Activation of EGFR leads to activation of c-Abl kinase (Srinivasan and Plattner, 2006) . Activated Src kinase in breast cancer cell lines also activate c-Abl kinase. Of note, EGFR activation does activate Src kinase (Osherov and Levitzki, 1994; Plattner et al., 1999) , but Src kinase can activate c-Abl in an EGFR-independent manner (Srinivasan and Plattner, 2006) . Activated c-Abl kinase enhances EGFR deregulation by prevention of EGFR internalization by phosphorylating Tyr 1173 of EGFR and prevention of Cbl translocation to the cell membrane (Tanos and Pendergast, 2006) . In NSCLC, and possibly breast cancer, lack of the Fus1 tumor suppressor protein would prevent downregulation of active c-Abl tyrosine kinase. Besides EGFR, the insulin-like growth factor 1 receptor (IGF-1R) has been shown to activate cAbl in breast cancer (Srinivasan et al., 2008) and thus IGF-1R may also play an important role in the constitutive activation of the c-Abl kinase in NSCLC.
for a matrix, a property of many tumor-forming cells. Imatinib mesylate (Gleevec), the Abl kinase inhibitor that is highly successful in the treatment of CML, strongly inhibited growth of H1299 cells in soft agar at physiological doses of imatinib (Lin et al., 2007) . Similarly, treatment of invasive human breast cancer cell line, MDA-MB-435, expressing activated c-Abl with imatinib in soft agar assays also lead to a decrease in size and number of colonies (Srinivasan et al., 2008) . While further studies, especially in animal models, are needed to confirm these findings, nevertheless these findings suggest that imatinib or other c-Abl kinase inhibitors may have medical utility in the treatment of some forms of NSCLC and breast cancer. Additional support for use of imatinib in treatment of NSCLC patients has been found in a recent mouse study and a patient study, both of which suggest that an important therapeutic option for NSCLC patients would be a combination of imatinib with chemotherapy for treatment of this aggressive cancer (Vlahovic et al., 2006; Negri et al., 2007) . Adding to c-Abl's possible oncogenic role in both NSCLC and breast cancer, a recent study has demonstrated that activated Abl kinase has a novel role in the regulation of EGFR endocytosis (Figure 3 ). Active Abl kinase phosphorylates EGFR on Tyr1173 and blocks Cbl translocation to the cell membrane, both events lead to the impairment of EGFR internalization (Tanos and Pendergast, 2006) . This role of active Abl kinase is of great significance, as overexpression of EGFR in both NSCLC and breast cancer is known to contribute to these malignancies. Therefore, it may be that inhibition of Abl kinase may lead to a decrease in cell surface EGFR in breast cancer and NSCLC.
In the NSCLC effects described by our group (Lin et al., 2007) , it appears that the key event leading to the activation of c-Abl kinase is either the functional or physical elimination of the Fus1 gene product. The loss of FUS1 gene product appears to occur in most NSCLC patients (Kondo et al., 2001; Ji et al., 2002; Prudkin et al., 2008) . In the case of breast cancer, activation of c-Abl appears to be a downstream effector of EGFR/IGF-1 receptor activation (Srinivasan and Plattner, 2006; Srinivasan et al., 2008) . This mechanism of Abl kinase activation may well contribute to activated c-Abl kinase in NSCLC as well, as EGFR is known to be overexpressed in NSCLC (Bunn and Franklin, 2002) . IGF-1R overexpression has been found in some lung cancers (LeRoith et al., 1995) , and a recent study has shown that inhibition of IGF-1R in human NSCLC cell line A549 results in cell cycle arrest, enhances the apoptotic response and inhibits: cell proliferation, adhesion, invasion and migration (Ma et al., 2007) . Therefore, it is possible that activation of cell surface receptors like EGFR might play a role in c-Abl activation in lung cancer, as well as breast cancers (Figure 3) . However, when Fus1 is expressed, even though receptor may be required for c-Abl activation, it may not be sufficient. We would propose the combination of receptor activation and Fus1 deficiency will lead to activated c-Abl and malignant properties of the effected lung cells. Also of interest, deletions in the 3p21.3 region have also been found in breast tumors, raising the question of whether some forms of breast cancer with elevated c-Abl may also be deficient in FUS1 (Ji et al., 2002) .
As pointed out by Srinivasan et al. (2008) , there is conflicting experimental evidence regarding the role of Abl kinases in proliferation and survival. Activation of c-Abl promotes proliferation, cell cycle progression and/ or cell survival in some cell contexts and inhibits growth and/or viability in others. Normal Abl in properly regulated cells may play dual roles in promotion of cell proliferation or inhibition of cell cycle or even cell apoptosis depending on the context. However, Abl activated by deregulated EGFR/IGF-1R, as in breast cancer cells (Srinivasan and Plattner, 2006; Srinivasan et al., 2008) or loss of Fus1, as in NSCLC cells (Lin et al., 2007) , is more similar to the constitutively activated Abl kinase found in mutant forms of Abl (v-Abl or Bcr-Abl), whose unregulated Abl kinase promote cell proliferation, cell survival and oncogenic transformation.
Summary
The results of two groups (Srinivasan and Plattner, 2006; Lin et al., 2007; Srinivasan et al., 2008) indicate that the Abl tyrosine kinase may play a crucial role in solid tumors malignancies involving NSCLC tumors and breast tumors, and that this important proto-oncogene may have an oncogenic impact beyond that of hematopoietic cell lineages. In the lung tumors, a known TSG product, Fus1, interacts with c-Abl causing downregulating of the Abl tyrosine kinase. NSCLC is frequently associated with loss of FUS1 gene expression, which may lead to c-Abl tyrosine kinase activation (Lin et al., 2007) . In the breast cancer system, activation of c-Abl tyrosine kinase appears downstream of deregulated EGFR and/ or the IGF-1 receptor (Srinivasan and Plattner, 2006; Srinivasan et al., 2008) .
It could be hypothesized from the results of these two groups that Abl activation in NSCLC and breast cancer may be a late occurring event that contributes to the aggressive growth and metastasis of these solid tumors. As Srinivasan et al. (2008) point out, since Abl kinase is activated by EGFR, IGF-1R and Src, Abl is a point of convergence of three pathways and therefore is an ideal target versus trying to target three separate pathways. We hypothesize that imatinib or other c-Abl kinase inhibitors, or treatment involving FUS1 itself, in the case of NSCLC (Ito et al., 2004) , when combined with current therapies for NSCLC and breast cancer, would greatly increase the efficacy of current therapy, and as Srinivasan and Plattner (2006) state, 'Abl kinase inhibitors may be effective in overcoming EGFR drug resistance'. Further investigation of c-Abl involvement in these two types of solid tumor malignancies is warranted.
